Literature DB >> 6248272

Primary hyperparathyroidism with intermittent hypercalcaemia: serial observations and simple diagnosis by means of an oral calcium tolerance test.

A E Broadus, R L Horst, E T Littledike, J E Mahaffey, H Rasmussen.   

Abstract

Ten patients with subtle primary hyperparathyroidism and intermittent hypercalcaemia were followed serially for periods of 2--18 months (mean 10 months). Fasting serum calcium was elevated (greater than 10.6 mg/dl) in only 20% of determinations and fluctuated widely (9.1--11.2 mg/dl), yet the patients displayed a continuous, rather than episodic, basic disease process as defined by increases in nephrogenous cyclic AMP and serum iPTH. Identical findings were noted in short-term (2--3 successive days) studies in twelve patients. In response to a 1000 mg oral calcium tolerance test, twelve patients with primary hyperparathyroidism and intermittent hypercalcaemia (basal serum calcium 10.2 +/- 0.2 mg/dl, mean +/- SD) displayed: (1) hyperabsorption of calcium (mean calciuric response twice normal); (2) induced-hypercalcaemia (mean serum calcium 11.4 mg/dl, with a mean increase of 1.2 mg/dl versus 0.2 mg/cl in normal subjects); and (3) abnormal parathyroid suppressibility (nephrogenous cyclic AMP 2.66 +/- 0.57 nmol/100 ml GF versus 0.95 +/- 0.40 nmol/100 ml GF in normal subjects, mean +/- SD). The patients demonstrated striking hypercalciuria (452 +/- 123 mg/24 h) on a 1000 mg metabolic calcium diet. Serum levels of 1,25(OH)2D3, measured in ten patients, were markedly elevated at 90 +/- 20 pg/ml (mean +/- SD), and there was a strong positive correlation between the values for 1,25(OH)2D3 and the calciuric response to the calcium tolerance test (r = 0.75, P less than 0.001). These results (1) indicate that the calcium tolerance test is a simple and reliable technique for diagnosis of patients with primary hyperparathyroidism and intermittent hypercalcaemia, and (2) emphasize the important pathophysiologic features of this subtle clinical variant of primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248272     DOI: 10.1111/j.1365-2265.1980.tb02704.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison.

Authors:  G Cadiot; P Houillier; A Allouch; M Paillard; M Mignon
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

2.  Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test.

Authors:  P Hagag; I Revet-Zak; N Hod; T Horne; M J Rapoport; M Weiss
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Spontaneous regression of hypercalcemia in a patient with primary hyperparathyroidism and prolactinoma.

Authors:  V Baskar; D Kamalakannan; B M Singh; J Odum
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

4.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

5.  Disappearing hypercalcaemia.

Authors:  G M Wood; B Sidhu; W A Saunders; A M Zalin; D A Heath
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.